UNSPSC 51283719: Cefonicid sodium

This classification denotes a cephalosporin antibiotic with the molecular formula C18H16N6O8S3.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F74MFL78A1, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((hydroxyphenylacetyl)amino)-8-oxo-3-(((1-(sulfomethyl)-1h-tetrazol-5-yl)thio)methyl)disodium salt, (6r-(6alpha,7beta(r*))) but more generally known as cefonicid sodium, which bears US NIH Compound Identifier 43593.

Most nations, for tariff and trade purposes, schedule cefonicid sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFONICID SODIUM remains US FDA's Preferred Term for this commodity. Cefonicid sodium bears US NLM identifiers UMLS ID C0886812 and NCI Concept Code C65300. SMILES: C1CCC(CC1)[C@H](C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC4NNNN4CS(=O)(=O)[O-])C(=O)[O-])O.[NA+].[NA+].

UNSPSC 51283719 Cefonicid sodium is a Commodity code representing injectable pharmaceutical products procured by state and local health departments and county public health agencies. The code covers the acquisition of specific antibiotic formulations and related injectable drugs for public health stockpiling, emergency preparedness, and direct healthcare delivery. State and local health authorities use this code to source pharmaceutical inventory through competitively bid contracts, often leveraging cooperative purchasing vehicles and piggyback arrangements to achieve volume pricing and streamlined procurement cycles.

Recent activity under this code is sparse and geographically limited. The most current example is the Illinois Department of Public Health's August 2026 piggyback pharmaceutical warehouse contract awarded to Chartwell Rx LLC through the MMCAP Infuse consortium, valued at $2,999,999.11 over the life of the three-year agreement with renewal options; while that award covered Doxycycline Hyclate and Ciprofloxacin Hydrochloride rather than cefonicid sodium specifically, it demonstrates the procurement pattern. A second recorded opportunity, Seminole County, Florida's June 2026 IFB for Naloxone and Safe Drug Deactivation Systems, diverges from the code's pharmaceutical scope and does not reflect typical cefonicid sodium demand. The code shows minimal recent solicitation activity, and opportunities when they do emerge tend to cluster among state health departments and county public health systems in the Southeast and Midwest rather than across all state and local jurisdictions.